ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
1,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2,1,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
2,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
2,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
3,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
3,2,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
3,3,Atrioventricular block,Cardiac conduction disorders,Cardiac arrhythmias,Card,N
3,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
